One Patient's hope: can an old TB drug help a rare paralysis condition?

NCT ID NCT07542548

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug D-cycloserine in a single patient with a rare genetic form of hereditary spastic paraplegia. The goal was to see if the drug is safe and can slow the disease by lowering certain fats (sphingolipids) in the body. The patient also took pyridoxine to help prevent side effects. Because it's only one person, the results are very early and may not apply to others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
D-cycloserine (with pyridoxine to reduce side effects)
What this could lead to
If it works, this could point toward a treatment for this specific genetic form of hereditary spastic paraplegia.
What could go wrong
This is a single-patient study, so results may not apply to others. The drug can cause serious side effects like liver problems, hearing loss, and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY SPASTIC PARAPLEGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.